Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Sino Biopharmaceutical ( (HK:1177) ).
Sino Biopharmaceutical has completed patient enrollment for a randomized, open-label Phase III trial of TQB2102, its independently developed HER2 bispecific antibody-drug conjugate for HER2-low recurrent or metastatic breast cancer. The company positions TQB2102 as a next-generation ADC that uses dual-epitope targeting, an enzyme-cleavable linker and an optimized drug-to-antibody ratio with a topoisomerase I inhibitor payload to balance efficacy and safety.
Phase Ib data presented at the 2025 ASCO meeting showed an objective response rate of 53.4% in heavily pretreated HER2-low patients, with 58.3% in the 7.5 mg/kg cohort and notable responses even after prior ADC failure, while maintaining a manageable safety profile. The move into late-stage development underscores Sino Biopharmaceutical’s ambition to address the large, underserved HER2-low breast cancer segment in China, reinforcing its strategic push to become a major player in breast cancer therapeutics and potentially improving outcomes for a sizable patient population with limited targeted options.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.90 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a China-focused pharmaceutical group specializing in innovative therapies, including oncology drugs targeting various breast cancer subtypes such as HER2-positive, HER2-low, HR+/HER2- and triple-negative disease. The company is building a comprehensive treatment portfolio that spans neoadjuvant, first-line, later-line and adjuvant settings to broaden options for cancer patients.
YTD Price Performance: 4.85%
Average Trading Volume: 65,700,656
Technical Sentiment Signal: Buy
Current Market Cap: HK$115.9B
Find detailed analytics on 1177 stock on TipRanks’ Stock Analysis page.